Ref ID: 19571
Author:
MD Richardson1,2*, ID Page1,2, RMK Rautemaa-Richardson1,2, DW Denning1,2
Author address:
1National Aspergillosis Centre, University Hospital of South Manchester, Manchester, UK
2Manchester Academic Health Science Centre, University of Manchester, Manchester, UK
Full conference title:
6th Advances Against Aspergillosis 2014
Abstract:
Purpose:
Measuring Aspergillus antibodies is an important part of the diagnostic pathway for allergic
bronchopulmonary aspergillosis (ABPA) and chronic pulmonary aspergillosis (CPA). It may
represent a major public health issue on a global scale as 20-35% of patients develop Aspergillus
antibodies following tuberculosis treatment and 63% of these develop pulmonary aspergillosis within
3 years. The worldwide 5 year period prevalence of (CPA) secondary to tuberculosis in, for example,
the Congo and Nigeria has been estimated at between 0.8 and 1.37 million cases, with 43 cases per
100,000 population. Detection of specific antibodies provides key diagnostic evidence in chronic
aspergillosis. There are numerous EIA formats for quantifying antibodies but these are not suitable
for use in developing countries with limited laboratory resources. Haemagglutination tests involve
coating erythrocytes with antigens. Erythrocytes clump together when antibodies cross-react with
antigens on more than one cell and become visible to the human eye. The method also detects all
Aspergillus antibody types. Its simplicity and speed (~2 hours) and commercial production make
it highly suited for epidemiological and prevalence studies in low and middle resource countries.
The goal was to compare the efficacy of an indirect haemagglutination assay designed to detect
Aspergillus agglutinating antibodies with an agar double diffusion system used for the detection of
Aspergillus precipitins.
Methods:
Serum samples from patients with a diagnosis of chronic pulmonary aspergillosis were tested by
ELI.H.A. Aspergillus indirect haemagglutination (ELITech MICROBIO, Signes, France), and by an
Aspergillus immunodiffusion system (Microgen Bioproducts Ltd, Camberley, UK). For the indirect
haemagglutination assay sera were serially diluted to 1:2560. For the immunodiffusion assay patient
sera were diluted to 1:16. The antigens used in these assays were a combination of cytoplasmic
(somatic) and culture filtration extracts.
Results:
In the indirect haemagglutination assay sera with a titre <1:320 were considered to be a nonsignificant
reaction. Sera with a titre equal to 1:320 were considered to be an indeterminant reaction.
Titres ≥ 1:640 indicated a significant reaction in favour of aspergillosis. A positive precipitin reaction
in the immunodiffusion test signified the presence of Aspergillus precipitating antibodies. The
performance of positive control sera in both assays was excellent, and reproducible. All sera positive
in one test were positive in the other. The concordance between titres determined by either the
indirect haemagglutination assay or the precipitin test were varied. High precipitin titres (1:8) were
recorded as >1:2560 in the agglutination assay. Precipitin titres of 1:4 were all in the positive range
of the agglutination assay. Sera recorded as weak precipitin positive (titre of 1:2) were all positive in
the agglutination test but with a range of agglutinin titres (1:320 – >1:2560). The immunodiffusion
test takes 5 days to perform. The total performance time of the indirect haemagglutination test is
3 hours.
Conclusion:
The EliTech indirect haemagglutination assay for the detection of Aspergillus antibody in patients
with chronic manifestations of pulmonary demonstrated has many advantages compared with
precipitin tests: it was rapid, very user friendly and easy to read. This is an ideal near point-of-care test
for field studies and for community clinics. Furthermore, this test can be used for screening patients
and support our efforts to understand the global epidemiology of chronic pulmonary aspergillosis.
Abstract Number: 97
Conference Year: 2014
Link to conference website: http://www.AAA2014.org
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a